Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin.

Abderrazek F, Chakroun T, Addad F, Dridi Z, Gerotziafas G, Gamra H, Hassine M, Elalamy I.

Thromb Res. 2010 Jun;125(6):e265-8. doi: 10.1016/j.thromres.2010.01.011.

PMID:
20138334
2.

Platelet glycoprotein IIIa (platelet antigen 1/platelet antigen 2) polymorphism and 1-year outcome in patients with stable coronary artery disease.

Addad F, Elalamy I, Chakroun T, Abderrazek F, Dridi Z, Hamdi S, Hassine M, Ben-Farhat M, Gerotziafas G, Hatmi M, Gamra H.

Blood Coagul Fibrinolysis. 2010 Oct;21(7):674-8. doi: 10.1097/MBC.0b013e32833e47c1.

PMID:
20739877
4.

Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.

Dropinski J, Musial J, Jakiela B, Wegrzyn W, Sanak M, Szczeklik A.

Thromb Haemost. 2005 Dec;94(6):1300-5.

PMID:
16411409
5.

Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms.

Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, Mauco G, Brizard A.

J Am Coll Cardiol. 2003 Sep 17;42(6):1115-9.

6.

Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation?

Papp E, Havasi V, Bene J, Komlosi K, Czopf L, Magyar E, Feher C, Feher G, Horvath B, Marton Z, Alexy T, Habon T, Szabo L, Toth K, Melegh B.

Ann Pharmacother. 2005 Jun;39(6):1013-8. Epub 2005 Apr 19.

PMID:
15840736
7.

Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination.

Cooke GE, Liu-Stratton Y, Ferketich AK, Moeschberger ML, Frid DJ, Magorien RD, Bray PF, Binkley PF, Goldschmidt-Clermont PJ.

J Am Coll Cardiol. 2006 Feb 7;47(3):541-6. Epub 2006 Jan 18.

8.

Association of the platelet glycoprotein receptor IIIa (PlA1/PlA1) genotype with coronary artery disease in Arabs.

Abu-Amero KK, Wyngaard CA, Dzimiri N.

Blood Coagul Fibrinolysis. 2004 Jan;15(1):77-9.

PMID:
15166947
9.

Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism.

Morawski W, Sanak M, Cisowski M, Szczeklik M, Szczeklik W, Dropinski J, Waclawczyk T, Ulczok R, Bochenek A.

J Thorac Cardiovasc Surg. 2005 Sep;130(3):791-6.

10.

Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.

Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD.

Circulation. 2009 Dec 22;120(25):2586-96. doi: 10.1161/CIRCULATIONAHA.109.900589. Epub 2009 Dec 7.

11.

Association of the platelet glycoprotein IIIa PlA1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients.

Gardemann A, Humme J, Stricker J, Nguyen QD, Katz N, Philipp M, Tillmanns H, Hehrlein FW, Rau M, Haberbosch W.

Thromb Haemost. 1998 Aug;80(2):214-7.

PMID:
9716139
12.

Screening for aspirin resistance in stable coronary artery patients by three different tests.

Chakroun T, Addad F, Abderazek F, Ben-Farhat M, Hamdi S, Gamra H, Hassine M, Ben-Hamda K, Samama MM, Elalamy I.

Thromb Res. 2007;121(3):413-8. Epub 2007 Jun 5.

PMID:
17553552
13.

The GPIIIa (beta3 integrin) PlA polymorphism in the early development of coronary atherosclerosis.

Mikkelsson J, Perola M, Penttilä A, Goldschmidt-Clermont PJ, Karhunen PJ.

Atherosclerosis. 2001 Feb 15;154(3):721-7.

PMID:
11257275
14.

High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial.

Motovska Z, Widimsky P, Kvasnicka J, Petr R, Bilkova D, Hajkova J, Marinov I, Simek S, Kala P; PRAGUE-8 study investigators.

Blood Coagul Fibrinolysis. 2009 Jun;20(4):257-62.

PMID:
19530321
15.

A case-control study of the association between polymorphisms of the endothelial nitric oxide synthase and glycoprotein IIIa genes and upper gastrointestinal bleeding in users of low-dose aspirin.

Piazuelo E, Fuentes J, García-González MA, Jiménez P, Lanas A.

Clin Ther. 2008 Jan;30(1):121-30. doi: 10.1016/j.clinthera.2008.01.020.

PMID:
18343248
16.

The prevalence of the platelet glycoprotein IIIa Pl(A1/A2) polymorphism in three South African ethnic groups and its effect on platelet function.

Naran NH, Chetty N, Crowther NJ.

Thromb Res. 2008;123(2):316-23. doi: 10.1016/j.thromres.2008.06.007. Epub 2008 Jul 25.

PMID:
18657307
17.

Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease.

Bernardo E, Angiolillo DJ, Ramírez C, Cavallari U, Trabetti E, Sabaté M, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C, Fernandez-Ortiz A.

Platelets. 2006 Dec;17(8):586-90.

PMID:
17127487
18.

Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease.

Gao F, Wang ZX, Men JL, Ren J, Wei MX.

Chin Med J (Engl). 2011 Jun;124(11):1731-4.

PMID:
21740787
19.

Factors responsible for "aspirin resistance" - can we identify them?

Postuła M, Tarchalska-Kryńska B, Filipiak KJ, Kosior D, Serafin A, Huczek Z, Opolski G.

Kardiol Pol. 2010 Apr;68(4):403-11; discussion 412-3.

20.

Prevalence and biologic profile of aspirin resistance in patients with angiographically proven coronary artery disease.

Narvaez I, Sagastagoitia JD, Vacas M, Saez Y, Lafita M, Monica S, de Lafuente JP, Molinero E, Iriarte JA.

Thromb Res. 2007;120(5):671-7. Epub 2007 Feb 28.

PMID:
17331566

Supplemental Content

Support Center